Effect of Esketamine and Lidocaine on Postoperative Chronic Pain and Long-term Survival in Patients Undergoing Hepatectomy
Not Applicable
Recruiting
- Conditions
- Postoperative Chronic Pain
- Interventions
- Drug: Esketamine-lidocaine groupOther: Placebo group
- First Posted Date
- 2025-01-16
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 304
- Registration Number
- NCT06778460
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer
- First Posted Date
- 2025-01-16
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 33
- Registration Number
- NCT06779539
Maternal Use of Antibiotics and the Risk of Congenital Malformations
Active, not recruiting
- Conditions
- Congenital Malformations
- Interventions
- Drug: Different categories of antibiotics
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 850000
- Registration Number
- NCT06770465
- Locations
- 🇨🇳
The West China Hospital of Sichuan university, Chengdu, Sichuan, China
Treatment of Sigmoid Volvulus
Completed
- Conditions
- Sigmoid Volvulus
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT06771349
- Locations
- 🇨🇳
Division of Gastrointestinal Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan, China
Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese Children
- First Posted Date
- 2025-01-08
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06763315
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
Phase 1
Not yet recruiting
- Conditions
- Esophagus Cancer
- Interventions
- First Posted Date
- 2024-12-31
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT06753747
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
Physiological Effects of APRVplus and TCAV in ARDS
Not Applicable
Completed
- Conditions
- ARDS (Acute Respiratory Distress Syndrome)
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06748807
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus
Phase 1
Recruiting
- Conditions
- HNSCCNeoadjuvant TherapyLysogenic HSV VirusImmunotherapyTargeted Therapy
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT06741982
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
Phase 2
Recruiting
- Conditions
- Hepato Cellular Carcinoma (HCC)
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT06742424
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC
Phase 1
Recruiting
- Conditions
- Gastric (Stomach) Cancer
- Interventions
- Drug: XELOX+Sintilimab+HBOT
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 57
- Registration Number
- NCT06742411
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
🇨🇳West China Hospital, Sichuan University, Chengdu, Sichuan, China
© Copyright 2025. All Rights Reserved by MedPath